Background. Children with T-lineage acute lymphoblastic leukemia (T-ALL) have an inferior outcome with combination chemotherapy compared to B-lineage ALL, and still about 30% of the patients relapse within the first 2 years following diagnosis. As CD34 has been related with poor outcome in ALL in general, we investigated the prognostic significance of the stem cell marker CD34, as well as the association of CD34 positivity with the expression of several multidrug resistance (MDR) genes. Procedure. In this retrospective study, we investigated the prognostic significance of the expression of the early T-cell differentiation marker CD34 and the expression of MDR genes in relation to outcome in a cohort of 72 newly diagnosed pediatric T-ALL patients. Results. CD34 expression was related to a poor 5-year disease-free-survival and a poor 5-year overall survival. Using the Cox proportional hazard model, CD34 expression predicted for increased risk for relapse and death. Expression of CD34 was associated with elevated MDR1 and MRP1 mRNA expression levels. For the entire T-ALL cohort, these expression levels of MDR1 or MRP1 did not independently predict for poor outcome. Conclusions. We conclude that CD34-positive T-ALL has a relatively poor survival that is not explained by the mRNA expression levels of MDR1, LRP, or MRP1.

, , , ,,
Pediatric Blood & Cancer
Erasmus MC: University Medical Center Rotterdam

van Grotel, M., van den Heuvel-Eibrink, M., van Wering, E., van Noesel, M., Kamps, W., Veerman, A. J. P., … Meijerink, J. (2008). CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatric Blood & Cancer, 51(6), 737–740. doi:10.1002/pbc.21707